Advertisement
UK markets closed
  • NIKKEI 225

    38,079.70
    +117.90 (+0.31%)
     
  • HANG SENG

    16,385.87
    +134.03 (+0.82%)
     
  • CRUDE OIL

    82.83
    +0.14 (+0.17%)
     
  • GOLD FUTURES

    2,399.20
    +10.80 (+0.45%)
     
  • DOW

    37,704.63
    -48.68 (-0.13%)
     
  • Bitcoin GBP

    50,495.77
    +982.05 (+1.98%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • NASDAQ Composite

    15,605.34
    -78.03 (-0.50%)
     
  • UK FTSE All Share

    4,290.02
    +17.00 (+0.40%)
     

Analysts’ Recommendations for Akcea and Its Peers in March

Analysts’ Recommendations for Akcea and Its Peers in March

Akcea Therapeutics (AKCA) is a late-stage biopharmaceutical company. AKCA’s pipeline includes volanesorsen, AKCEA-APO, AKCEA-ANGPTL, and AKCEA-APOCIII, which are based on Ionis Pharmaceuticals’ (IONS) antisense technology. In March 2018, two of the four analysts covering Akcea Therapeutics have given the stock “buy” or higher ratings, while two have given it “hold” ratings.